Corbrin 胶囊对尿毒症患者营养不良、炎症和动脉粥样硬化综合征的疗效和安全性：系统评价和荟萃分析。

Efficacy and safety of Corbrin Capsule on malnutrition, inflammation, and atherosclerosis syndrome in patients with uremia: systematic review and meta-analysis.

机构信息

Department of Nephrology, Yan'an Hospital of Kunming City, Kunming, China.

出版信息

Ann Palliat Med. 2022 Apr;11(4):1431-1440. doi: 10.21037/apm-22-291.

DOI:10.21037/apm-22-291

PMID:35523751

Abstract

BACKGROUND

Uremia is a clinical syndrome caused by the development of chronic renal failure to the end-stage. Corbrin Capsule has the effect of tonifying the lungs and kidneys and improving the essence and qi, which can improve the metabolic disorders of the body. However, there is currently no systematic evaluation of the efficacy of Corbrin Capsule in the treatment of uremia malnutrition, inflammation, and atherosclerosis (MIA) syndrome. This paper aiming to provide a reference for improving the prognosis of uremic MIA patients.

METHODS

According to the PICOS principle, the literature inclusion and exclusion criteria were formulated. The databases such as PubMed, Web of Science, Embase, and Cochrane Library were searched by computer using "Corbrin Capsule", "uremia", "MIA syndrome", and "kidney function" as search items. The outcome indicators were body mass index (BMI), C-reactive protein (CRP), blood urea nitrogen (BUN), and serum creatinine (sCr). Subsequently, the Cochrane Reviewer's Handbook 4.2.5 was adopted to assess the literature quality. The conventional treatment combined with Corbrin Capsule was defined as MIA/treatment group, and the conventional treatment was defined as the control group. The Review Manager (RevMan) 5.3 software was used to conduct a meta-analysis of the experimental data.

RESULTS

A total of 6 suitable included articles were selected, including 894 patients. The included literature was analyzed and found that there was no obvious publication bias. According to the results of meta-analysis, the total BMI score was mean difference (MD) [95% confidence interval (CI)]: -0.10 (-3.44 to 3.24) with Z=0.06 and P=0.95. The CRP total score was MD (95% CI): 1.40 (0.34 to 2.46) with Z=2.58 and P=0.010. The BUN index was MD (95% CI): -1.15 (-3.05 to 0.75) with Z=1.18, P=0.24. Analysis result of sCr index data was MD (95% CI): -72.82 (-202.16 to 56.52) with Z=1.10 and P=0.27.

DISCUSSION

Corbrin Capsule can effectively improve the relevant physiological indicators of patients with uremic MIA syndrome. However, the outcome indicators included in this study were insufficient, and it is necessary to further expand the sample size and outcome indicators in the future.

摘要

背景

尿毒症是慢性肾功能衰竭发展至终末期所引起的一种临床综合征。肾衰宁胶囊具有益肺补肾、益气养精的功效，可改善机体代谢紊乱。但目前尚缺乏系统评价肾衰宁胶囊治疗尿毒症营养不良-炎症-动脉粥样硬化（MIA）综合征的疗效，本文旨在为改善尿毒症 MIA 患者的预后提供参考。

方法

根据 PICOS 原则制定文献纳入和排除标准，计算机检索 PubMed、Web of Science、Embase 和 Cochrane Library 等数据库，以“Corbrin Capsule”“uremia”“MIA syndrome”和“kidney function”为检索词进行检索。结局指标为体质量指数（BMI）、C 反应蛋白（CRP）、血尿素氮（BUN）和血清肌酐（sCr）。随后采用 Cochrane 评价员手册 4.2.5 对文献质量进行评价，常规治疗联合肾衰宁胶囊治疗定义为 MIA/治疗组，常规治疗定义为对照组。采用 Review Manager（RevMan）5.3 软件对实验数据进行 Meta 分析。

结果

共纳入 6 篇符合标准的文献，共计 894 例患者。对纳入文献进行分析后发现，不存在明显发表偏倚。Meta 分析结果显示，总 BMI 评分的均数差（MD）[95%置信区间（CI）]为-0.10（-3.44～3.24），Z=0.06，P=0.95；CRP 总评分 MD（95%CI）为 1.40（0.34～2.46），Z=2.58，P=0.01；BUN 指数 MD（95%CI）为-1.15（-3.05～0.75），Z=1.18，P=0.24；sCr 指数 MD（95%CI）为-72.82（-202.16～56.52），Z=1.10，P=0.27。